{"id":381631,"date":"2020-11-16T08:03:37","date_gmt":"2020-11-16T13:03:37","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=381631"},"modified":"2020-11-16T08:03:37","modified_gmt":"2020-11-16T13:03:37","slug":"chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","title":{"rendered":"Chiasma to Participate in the Jefferies Virtual London Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEEDHAM, Mass., Nov.  16, 2020  (GLOBE NEWSWIRE) &#8212; Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that management will be participating in the Jefferies Virtual London Healthcare Conference, which is being held November 17-19. Details of the presentation are as follows:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:10%;width:10%;min-width:10%\">Date:<\/td>\n<td style=\"max-width:90%;width:90%;min-width:90%\">Thursday, November 19, 2020<\/td>\n<\/tr>\n<tr>\n<td>Time:<\/td>\n<td>2:55pm ET<\/td>\n<\/tr>\n<tr>\n<td>Format:<\/td>\n<td>Fireside chat<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">A live audio webcast of the Jefferies fireside chat will be available in the News and Investors section of Chiasma\u2019s website at www.chiasma.com. A replay will be available for 90 days.<\/p>\n<p align=\"justify\">\n        <strong>About Chiasma<br \/><\/strong>Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE<sup>\u00ae<\/sup>) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. On June 26, 2020, Chiasma received FDA approval of MYCAPSSA for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA, the first and only oral somatostatin analog approved by the FDA, is available for commercial sale in the United States. Chiasma is headquartered in Needham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HRc-AfVhgsyE5lWCFfPp4FSkijLiIg4MlqddPM2u-1dWqZGqFyHo7Uih4iy_7qObR988go5MrBpYUCMYUMpjIg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.chiasma.com<\/a>.<\/p>\n<p>\n        <strong>Investor Relations and Corporate Communications:<\/strong><br \/>\n        <br \/>Ashley Robinson<br \/>LifeSci Advisors, LLC<br \/>617-430-7577<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UXNJtaOiLNvrLJ6HB9xC76HWB4U2rC_P9cwbPB6Tyyl8_UO8eZaHayocbyRHHQe_7rXVnuqL35hMjEbNtt59hDzBufRkJikfarQW26um9Co=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">arr@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Relations:<\/strong><br \/>\n        <br \/>Patrick Bursey<br \/>LifeSci Communications<br \/>646-876-4932<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BzdBArnBQ40AdFH3WUr4FWZ7sfbT-j7VYTalLNmyJYdxkixqEpk85CkOaoXkOv-9Xrl63Vzr2modD9Yh44Sqzrf4bddfqcCRGGKExT6WSlM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">pbursey@lifescicomms.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjM0OSMzODI3OTk2IzUwMDA3MTQ2Mw==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/a2cd7a24-63d9-420e-8e8c-b265f18f5f78\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEEDHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that management will be participating in the Jefferies Virtual London Healthcare Conference, which is being held November 17-19. Details of the presentation are as follows: Date: Thursday, November 19, 2020 Time: 2:55pm ET Format: Fireside chat A live audio webcast of the Jefferies fireside chat will be available in the News and Investors section of Chiasma\u2019s website at www.chiasma.com. A replay will be available for 90 days. About ChiasmaChiasma is a commercial-stage biopharmaceutical company focused on developing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Chiasma to Participate in the Jefferies Virtual London Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-381631","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Chiasma to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chiasma to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEEDHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that management will be participating in the Jefferies Virtual London Healthcare Conference, which is being held November 17-19. Details of the presentation are as follows: Date: Thursday, November 19, 2020 Time: 2:55pm ET Format: Fireside chat A live audio webcast of the Jefferies fireside chat will be available in the News and Investors section of Chiasma\u2019s website at www.chiasma.com. A replay will be available for 90 days. About ChiasmaChiasma is a commercial-stage biopharmaceutical company focused on developing &hellip; Continue reading &quot;Chiasma to Participate in the Jefferies Virtual London Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-16T13:03:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjM0OSMzODI3OTk2IzUwMDA3MTQ2Mw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Chiasma to Participate in the Jefferies Virtual London Healthcare Conference\",\"datePublished\":\"2020-11-16T13:03:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\"},\"wordCount\":280,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjM0OSMzODI3OTk2IzUwMDA3MTQ2Mw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\",\"name\":\"Chiasma to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjM0OSMzODI3OTk2IzUwMDA3MTQ2Mw==\",\"datePublished\":\"2020-11-16T13:03:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjM0OSMzODI3OTk2IzUwMDA3MTQ2Mw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjM0OSMzODI3OTk2IzUwMDA3MTQ2Mw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chiasma to Participate in the Jefferies Virtual London Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Chiasma to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Chiasma to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk","og_description":"NEEDHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that management will be participating in the Jefferies Virtual London Healthcare Conference, which is being held November 17-19. Details of the presentation are as follows: Date: Thursday, November 19, 2020 Time: 2:55pm ET Format: Fireside chat A live audio webcast of the Jefferies fireside chat will be available in the News and Investors section of Chiasma\u2019s website at www.chiasma.com. A replay will be available for 90 days. About ChiasmaChiasma is a commercial-stage biopharmaceutical company focused on developing &hellip; Continue reading \"Chiasma to Participate in the Jefferies Virtual London Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-16T13:03:37+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjM0OSMzODI3OTk2IzUwMDA3MTQ2Mw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Chiasma to Participate in the Jefferies Virtual London Healthcare Conference","datePublished":"2020-11-16T13:03:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/"},"wordCount":280,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjM0OSMzODI3OTk2IzUwMDA3MTQ2Mw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/","name":"Chiasma to Participate in the Jefferies Virtual London Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjM0OSMzODI3OTk2IzUwMDA3MTQ2Mw==","datePublished":"2020-11-16T13:03:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjM0OSMzODI3OTk2IzUwMDA3MTQ2Mw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjM0OSMzODI3OTk2IzUwMDA3MTQ2Mw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chiasma-to-participate-in-the-jefferies-virtual-london-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Chiasma to Participate in the Jefferies Virtual London Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=381631"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381631\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=381631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=381631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=381631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}